Clinical trials testing recombinant PF-4 have been completed in metastatic colon cancer [86], AIDS-related Kaposi’s sarcoma [87,88], metastatic melanoma, renal cell carcinoma [89] and high-grade glioma [90]. This evidence concerns the gene PF4 and renal cell carcinoma.